Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
Trinity Biotech (NASDAQ:TRIB) Cut to Sell at StockNews.com
StockNews.com cut shares of Trinity Biotech (NASDAQ:TRIB – Free Report) from a hold rating to a sell rating in a research report released on Thursday. Trinity Biotech Stock Up 1.6 % Shares of TRIB ...
Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com
Research analysts at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the stock. Trinity ...
Drug Delivery Business1d
Trinity Biotech to undergo strategic realignment, focus on CGM development
Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.
Hosted on MSN29d
Trinity Biotech announces breakthrough in CGM technology
John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...
Nasdaq1mon
Trinity Biotech Reveals New Findings From Pre-Pivotal Trial Of Next-Gen CGM
(RTTNews) - Trinity Biotech plc (TRIB), a biotechnology company focused on diabetes management, on Thursday announced notable advances in its pre-pivotal trial for its next-generation continuous ...